차백신연구소
Financials
Valuation Metrics
차백신연구소's Market Cap is ₩1213B. At end of 2025 it was ₩818B. Ranked #1165 of 2,421 in KR market (top 48%), #619 of 1,640 on KOSDAQ (top 38%), #135 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 121.33B KRW | KR#1,165/2,421 Sec#135/231 |
| Revenue | 158.6M KRW | KR#2,392/2,421 Sec#223/231 |
| Net Income | -14.42B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 21.15B KRW | KR#2,376/2,421 Sec#226/231 |
| Net Assets | 9.89B KRW | KR#2,375/2,421 Sec#224/231 |
| Employees | 56 | KR#2,005/2,421 Sec#180/231 |
| Value | ||
| P/B | 12.27x | KR#2,374/2,421 Sec#214/231 |
| P/S | 764.90x | KR#2,411/2,421 Sec#226/231 |
| FCF Yield | -9.18% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -145.79% | KR#2,370/2,421 Sec#223/231 |
| ROA | -68.19% | KR#2,381/2,421 Sec#221/231 |
| Op. Margin | -8178.60% | KR#2,392/2,421 Sec#223/231 |
| Revenue Growth | -57.21% | KR#2,302/2,421 Sec#205/231 |
| Financial Health | ||
| Debt Ratio | 113.79% | KR#1,660/2,421 Sec#190/231 |
| Total Debt | 6.19B KRW | KR#1,746/2,421 Sec#164/231 |
| FCF | -11.13B KRW | KR#1,740/2,421 Sec#154/231 |
| Cash | 6.94B KRW | KR#1,881/2,421 Sec#167/231 |
| Current Ratio | 1.92x | KR#909/2,421 Sec#102/231 |
| Performance | ||
| 1Y Return | 49.11% | KR#267/2,421 Sec#13/231 |
| 1M Return | 88.31% | KR#21/2,421 Sec#2/231 |
| From 52W High | -37.65% | KR#824/2,421 Sec#56/231 |
| 1Y MDD | -67.42% | KR#1,860/2,421 Sec#157/231 |
| Trading | ||
| Volume | 1,413,767 shares | KR#100/2,421 Sec#7/231 |
| Trading Value | 5.69B KRW | KR#347/2,421 Sec#31/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | -498 KRW | KR—/2,421 Sec—/231 |
| BPS | 342 KRW | KR#2,407/2,421 Sec#229/231 |
Company Info
CHA Vaccine Institute, a bio venture company established in 2000, joined the CHA Hospital/CHA Bio Group in 2011 when CHA Biotech became its largest shareholder. Utilizing its independently developed immune-enhancing platform technology, the company is developing next-generation vaccines, including therapeutic vaccines for chronic Hepatitis B, and anti-cancer immunotherapeutics. Its immune enhancers boost immune responses to vaccine antigens; specifically, Lipo-pam® is ideal for therapeutic vaccine development due to its ability to induce strong cellular immune responses. CHA Vaccine Institute is headquartered in Seongnam-si, Gyeonggi-do.